A Randomized, Open-label Study to Evaluate the Pharmacokinetics of a Single Subcutaneous Administration of 50 mg or 100 mg Golimumab in a Pre-filled Syringe Formulation to Healthy Male Chinese Subjects.
Phase of Trial: Phase I
Latest Information Update: 09 Jul 2014
At a glance
- Drugs Golimumab (Primary)
- Indications Arthritis; Psoriatic arthritis; Ulcerative colitis
- Focus Pharmacokinetics
- Sponsors Centocor
- 24 Aug 2013 Results published in the Clinical Drug Investigation.
- 26 Apr 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 10 Feb 2011 New trial record